Krystal Biotech KRYS 深 沪
等待开盘 10-30 09:30:00 美东时间
324.55
+3.130
+0.97%
华盛通- 最 高326.98
- 今 开323.77
- 成交量 19.08万股
- 最 低 319.43
- 昨 收 321.42
- 总市值 96.06亿
- 52周最高 382.535
- 市盈率 静 47.46
- 换手率 0.64%
- 52周最低 197.13
- 委 比 70.74%
- 总股本 2959.88万
- 历史最高 382.535
- 量 比 0.83
- 振 幅 2.35%
- 历史最低 8.03
- 每 手 1
- 风险率 48.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Krystal Biotech收跌2.7%，成交额8438.88万美元
10月24日，Krystal Biotech（KRYS）收跌2.7%，报311.5美元，成交额8438.88万美元，市值92.2亿美元。 行情数据 • 开盘价...
10-24 04:56
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market capitalization of $9.51 billion. Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 ...
10-23 07:15
Krystal Biotech收跌4.07%，成交额7203.38万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 04:56
美股大行评级 | 潜在涨幅279.75%！Jones Trading维持Contineum Therapeutics(CTNM)"买入"评级，目标价上调至30美元
今日重点评级关注：Jones Trading：维持Contineum Therapeutics"买入"评级，目标价从24美元升至30美元；StoneX：维持Forum Markets"投机性买入"评级，目标价从9美元升至12美元
10-16 12:30
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.
10-16 01:20
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech Inc. (NASDAQ:KRYS) on Thursday released a clinical update for its intratumoral immunotherapy, KB113. The treatment demonstrated initial proof of concept by reducing basal cell carcinomas (BCCs) in patients suffering from Gorlin syndrome. This targeted therapy functions by driving sus...
10-16 00:46
Krystal Biotech advances KB113 for Gorlin syndrome
The latest update is out from Krystal Biotech ( ($KRYS) ). On October 15, 2026,...
10-15 19:28
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Krystal Biotech's KB113, an intratumoral immunotherapy, showed promising results in a pilot study for Gorlin syndrome patients with basal cell carcinomas (BCCs). Over 80% of assessed BCC lesions regressed, including non-injected lesions, indicating an abscopal effect. KB113 was well-tolerated, with mild to moderate adverse events. Histological clearance of injected lesions was confirmed in all three patients. The data will be presented at the 14t...
10-15 11:00
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 33.19% on an annualized basis producing an average annual return of 45.63%. Currently, Krystal Biotech has a market capitalization of $9.78 billion. Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock ...
10-06 23:45
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
